Patent Costs Pending

Image: Erica Johnson The idea behind the US patent system is relatively simple: register an invention with the government and get a 20-year monopoly to sell it, after which point your idea goes into the public domain. Sounds straightforward, right? Not if you're a patent lawyer. Underneath that basic framework is a legal infrastructure filled with so many loopholes, twists, and turns that, were it pipework, it would make any plumber sweat. That system became a lot more complicated when the U

Written bySam Jaffe
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The idea behind the US patent system is relatively simple: register an invention with the government and get a 20-year monopoly to sell it, after which point your idea goes into the public domain. Sounds straightforward, right? Not if you're a patent lawyer. Underneath that basic framework is a legal infrastructure filled with so many loopholes, twists, and turns that, were it pipework, it would make any plumber sweat.

That system became a lot more complicated when the US Supreme Court, ruling in a case now known as Festo,1 set new standards for inventors' descriptions of patents. The high court decision, which set aside an onerous lower court ruling, should still worry most patent holders--especially those with life sciences patents--and fatten patent lawyers' paychecks. "There were two parts of the Festo ruling, and everybody forgets that only one of them was overturned," says Dianne Elderkin, a partner with Philadelphia-based Woodcock ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies